Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 32
- Registration Number
- NCT05826574
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
PanACEA - STEP2C -01
- Conditions
- Other Specified Pulmonary TuberculosisPulmonary Tuberculosis
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 270
- Registration Number
- NCT05807399
- Locations
- 🇲🇼
Kamuzu College of Health Sciences (formerly College of Medicine), Blantyre, Malawi
🇹🇿Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania
🇺🇬Makerere University Lung Institute Limited, Kampala, Uganda
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Tuberculosis, PulmonaryTuberculosis Infection
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 28
- Registration Number
- NCT05720767
- Locations
- 🇺🇸
PPD Austin, Austin, Texas, United States
A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT05685719
- Locations
- 🇨🇳
Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang, China
Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 31
- Registration Number
- NCT05635110
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, Australia
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 59
- Registration Number
- NCT05602597
- Locations
- 🇺🇸
QPS- Miami, Miami, Florida, United States
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
- Conditions
- Leprosy
- Interventions
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Institute of Tropical Medicine, Belgium
- Target Recruit Count
- 124000
- Registration Number
- NCT05597280
- Locations
- 🇰🇲
Fondation Damien, Moroni, Comoros
Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05592223
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05577624
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc 3402 Kinsman Boulevard, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.